Capstan Therapeutics scientists demonstrate that lipid nanoparticles can engineer CAR T cells within the body without laboratory cell manufacturing and ex vivo expansion. The method using targeted ...
MedPage Today on MSN
CAR7 Gene Therapy Shows Promise in T-Cell ALL
The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...
The TIME trial: Phase II randomized controlled trial of time-of-day–specified immunotherapy for advanced melanoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback